Atnahs Acquires Rights for Bonviva^® and Bondronat^®

Basildon, UK.

Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of worldwide rights (except for Japan and the US) for Bondronat® and Bonviva® from F. Hoffmann-La Roche Limited (“Roche”).

Bonviva® and Bondronat® are injectable and tablet forms of ibandronic acid used for the treatment of osteoporosis and metastatic bone disease respectively. It is Atnahs’ fourth product acquisition from Roche, following Naprosyn®/ Anaprox® and Toradol® in 2015, and Kytril® earlier this year.

Amit Patel, Atnahs’ Managing Director, comments,

“The acquisition of Bonviva® and Bondronat® expands our global presence to over 130 territories worldwide and enhances our presence in Latin America, Middle East, Africa and South East Asia. It also gives us a foothold in China and Russia for the first time. We are looking forward to leveraging our international distribution network to make the medicines available to all the patients who need them.

In addition, Bonviva® and Bondronat® serve to bolster our Women’s Health portfolio. Alongside Pain/ Inflammation and CNS, we see Women’s Health as one of our three strategic therapeutic areas with promising opportunities for investment and development.”

Tony Playle, Atnahs’ Strategy Director, further comments,

“We are delighted to continue developing our relationship with Roche with this, our fourth product acquisition. Our team is now focused once again on working in partnership with Roche on transitioning the medicine seamlessly into our international distribution network. We pride ourselves upon offering our large cap and specialty pharma partners a one-stop shop for the divestment of mature branded medicines globally.”

About Atnahs

Atnahs is a family-owned specialty pharmaceutical business, focussed upon acquiring mature branded medicines globally, developing line extensions to them, and developing its own niche generic medicines. Atnahs has now completed eight major acquisitions since its inception in 2013, and now operates a portfolio of over 15 key medicines across more than 130 markets.